Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells

Deniz Cansen Kahraman; Gilles Hanquet; Loïc Jeanmart; Steve Lanners; Peter Šramel; Andrej Boháč; Rengul Cetin-Atalay

doi:10.1039/c6md00392c

Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells

Deniz Cansen Kahraman, Gilles Hanquet, Loïc Jeanmart, Steve Lanners, Peter Šramel, Andrej Boháč, Rengul Cetin-Atalay

Unite de recherche en chimie organique

Résultats de recherche: Contribution à un journal/une revue › Article › Revue par des pairs

Résumé

Bioactivities of quinoides 1-5 and VEGFR2 TKIs 6-10 in hepatocellular cancer (HCC) and cancer stem cells (HCSCs) were studied. The compounds exhibited IC₅₀ values in μM concentrations in HCC cells. Quinoide 3 was able to eradicate cancer stem cells, similar to the action of the stem cell inhibitor DAPT. However, the more cytotoxic VEFGR TKIs (IC₅₀: 0.4-3.0 μM) including sorafenib, which is the only FDA approved drug for the treatment of HCC, enriched the hepatocellular cancer stem cell population by 2-3 fold after treatment. An aggressiveness factor (A_F) was proposed to quantify the characteristics of drug candidates for their ability to eradicate the CSC subpopulation. Considering the tumour heterogeneity and marker positive cancer stem cell like subpopulation enrichment upon treatments in patients, this study emphasises the importance of the chemotherapeutic agent choice acting differentially on all the subpopulations including marker-positive CSCs.

langue originale	Anglais
Pages (de - à)	81-87
Nombre de pages	7
journal	MedChemComm
Volume	8
Numéro de publication	1
Date de mise en ligne précoce	7 oct. 2016
Les DOIs	https://doi.org/10.1039/c6md00392c
Etat de la publication	Publié - 2017

SDG des Nations Unies

Ce résultat contribue à ou aux Objectifs de développement durable suivants

Accès au document

10.1039/c6md00392c

Autres fichiers et liens

Link to publication in Scopus

Physico-chimie et caractérisation (PC2)
Johan Wouters (!!Manager) & Carmela Aprile (!!Manager)
Plateforme technologique Caracterisation physico-chimiques
Equipement/installations: Plateforme technolgique

Contient cette citation

@article{c2f8d3b5148f489fb48de313a171855f,

title = "Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells",

abstract = "Bioactivities of quinoides 1-5 and VEGFR2 TKIs 6-10 in hepatocellular cancer (HCC) and cancer stem cells (HCSCs) were studied. The compounds exhibited IC50 values in μM concentrations in HCC cells. Quinoide 3 was able to eradicate cancer stem cells, similar to the action of the stem cell inhibitor DAPT. However, the more cytotoxic VEFGR TKIs (IC50: 0.4-3.0 μM) including sorafenib, which is the only FDA approved drug for the treatment of HCC, enriched the hepatocellular cancer stem cell population by 2-3 fold after treatment. An aggressiveness factor (AF) was proposed to quantify the characteristics of drug candidates for their ability to eradicate the CSC subpopulation. Considering the tumour heterogeneity and marker positive cancer stem cell like subpopulation enrichment upon treatments in patients, this study emphasises the importance of the chemotherapeutic agent choice acting differentially on all the subpopulations including marker-positive CSCs.",

author = "Kahraman, {Deniz Cansen} and Gilles Hanquet and Lo{\"i}c Jeanmart and Steve Lanners and Peter {\v S}ramel and Andrej Boh{\'a}{\v c} and Rengul Cetin-Atalay",

year = "2017",

doi = "10.1039/c6md00392c",

language = "English",

volume = "8",

pages = "81--87",

journal = "MedChemComm",

issn = "2040-2503",

publisher = "Royal Society of Chemistry",

number = "1",

}

TY - JOUR

T1 - Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells

AU - Kahraman, Deniz Cansen

AU - Hanquet, Gilles

AU - Jeanmart, Loïc

AU - Lanners, Steve

AU - Šramel, Peter

AU - Boháč, Andrej

AU - Cetin-Atalay, Rengul

PY - 2017

Y1 - 2017

N2 - Bioactivities of quinoides 1-5 and VEGFR2 TKIs 6-10 in hepatocellular cancer (HCC) and cancer stem cells (HCSCs) were studied. The compounds exhibited IC50 values in μM concentrations in HCC cells. Quinoide 3 was able to eradicate cancer stem cells, similar to the action of the stem cell inhibitor DAPT. However, the more cytotoxic VEFGR TKIs (IC50: 0.4-3.0 μM) including sorafenib, which is the only FDA approved drug for the treatment of HCC, enriched the hepatocellular cancer stem cell population by 2-3 fold after treatment. An aggressiveness factor (AF) was proposed to quantify the characteristics of drug candidates for their ability to eradicate the CSC subpopulation. Considering the tumour heterogeneity and marker positive cancer stem cell like subpopulation enrichment upon treatments in patients, this study emphasises the importance of the chemotherapeutic agent choice acting differentially on all the subpopulations including marker-positive CSCs.

AB - Bioactivities of quinoides 1-5 and VEGFR2 TKIs 6-10 in hepatocellular cancer (HCC) and cancer stem cells (HCSCs) were studied. The compounds exhibited IC50 values in μM concentrations in HCC cells. Quinoide 3 was able to eradicate cancer stem cells, similar to the action of the stem cell inhibitor DAPT. However, the more cytotoxic VEFGR TKIs (IC50: 0.4-3.0 μM) including sorafenib, which is the only FDA approved drug for the treatment of HCC, enriched the hepatocellular cancer stem cell population by 2-3 fold after treatment. An aggressiveness factor (AF) was proposed to quantify the characteristics of drug candidates for their ability to eradicate the CSC subpopulation. Considering the tumour heterogeneity and marker positive cancer stem cell like subpopulation enrichment upon treatments in patients, this study emphasises the importance of the chemotherapeutic agent choice acting differentially on all the subpopulations including marker-positive CSCs.

UR - http://www.scopus.com/inward/record.url?scp=85010782551&partnerID=8YFLogxK

U2 - 10.1039/c6md00392c

DO - 10.1039/c6md00392c

M3 - Article

AN - SCOPUS:85010782551

SN - 2040-2503

VL - 8

SP - 81

EP - 87

JO - MedChemComm

JF - MedChemComm

IS - 1

ER -

Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells

Résumé

SDG des Nations Unies

Accès au document

Autres fichiers et liens

Empreinte digitale

Équipement

Physico-chimie et caractérisation (PC2)

Contient cette citation